Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity

Cancer Gene Therapy

Volumn 16, Issue 9, 2009, Pages 673-682

  Osada, T ^a   Yang, X Y ^a   Hartman, Z C ^a   Glass, O ^a   Hodges, B L ^b   Niedzwiecki, D ^c   Morse, M A ^c,d   Lyerly, H K ^a,c,d   Amalfitano, A ^e   Clay, T M ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Prothelia Inc   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d Department of Medicine ^*  (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Ad5 vectors; Adenovirus; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN E1;

ADENOVIRUS 5; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ADENOVIRUS E2 PROTEINS; ADENOVIRUS E3 PROTEINS; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE DELETION; GENETIC VECTORS; HUMANS; KILLER CELLS, NATURAL; KINETICS; MICE; MICE, INBRED C57BL;

ADENOVIRIDAE; MIRIDAE;

EID: 68949205787     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.17     Document Type: Article

References (33)

1. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238.
2. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002; 20: 2197-2207.
3. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
4. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005; 11: 3017-3024.
5. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996; 334: 1185-1187.
6. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005; 16: 149-156.
7. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-629.
8. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499-503.
9. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 2004; 78: 7392-7399.
10. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 2007; 15: 393-403.
11. Barouch DH, Pau MG, Custers JH, Kudstaal W, Kostense S, HavengaMJ et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172: 6290-6297.
12. Hodges BL, Evans HK, Everett RS, Ding EY, Serra D, Amalfitano A. Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications. J Virol 2001; 75: 5913-5920.
13. Hodges BL, Serra D, Hu H, Begy CA, Chamberlain JS, Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2000; 2: 250-259.
14. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
15. Everett RS, Hodges BL, Ding EY, Xu F, Serra D, Amalfitano A. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 2003; 14: 1715-1726.
16. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 2004; 78: 2666-2673.
17. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174: 7179-7185.
18. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55: 355-372.
19. Oh ST, Kim CH, Park MY, Won EH, Sohn HJ, Cho HI et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006; 24: 2860-2868.
20. Malowany JI, McCormick S, Santosuosso M, Zhang X, Aoki N, Ngai P et al. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptideor protein-loaded counterparts. Mol Ther 2006; 13: 766-775.
21. Steitz J, Tormo D, Schweichel D, Tuting T. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Ther 2006; 13: 318-325.
22. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441: 239-2343.
23. Tang J, Olive M, Champagne K, Flomenberg N, Eisenlohr L, Hsu S et al. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther 2004; 11: 1408-1415.
24. Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Ségard H et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002; 76: 127-135.
25. Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 2007; 81: 1796-1812.
26. Ding EY, Hodges BL, Hu H, McVie-Wylie AJ, Serra D, Migone FK et al. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum Gene Ther 2001; 12: 955-965.
27. Harris JD, Graham IR, Schepelmann S, Stannard AK, Roberts ML, Hodges BL et al. Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE. Hum Mol Genet 2002; 11: 43-58.
28. Ding E, Hu H, Hodges BL, Migone F, Serra D, Xu F et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002; 5: 436-446.
29. Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 2002; 13: 311-320.
30. Hartman ZC, Appledorn DM, Serra D, Glass O, Mendelson TB, Clay TM et al. Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology 2008; 374: 453-467.
31. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 2005; 73: 6885-6891.
32. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 2002; 76: 12775-12782.
33. Varnavski AN, Schlienger K, Bergelson JM, Gao GP, Wilson JM. Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum Gene Ther 2003; 14: 533-544.